Biomind Labs, a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, announced the successful conclusion of the Phase 2 clinical trial of its proprietary 5-Metoxi-N,N-dimethyltryptamine (5-MeO-DMT)-based BMND08, a sublingual formulation designed for the treatment of depression and anxiety in Alzheimer's disease. Led by Biomind’s Clinical Advisor Neuroscientist Dr. Martín Bruno, the trial showcased remarkable advancements in treatment safety and efficacy.

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg, administered once weekly over four consecutive weeks.

Alejandro Antalich, CEO of Biomind Labs emphasized: “Finding a dose that doesn't produce undesirable or harmful side effects is of paramount importance due to the delicate nature of individuals facing Alzheimer’s- related MCI. Patients may be reluctant to continue treatment if they experience adverse reactions, leading to non-adherence and reduced efficacy of the medication; healthcare professionals and regulatory authorities are more likely to approve and endorse treatments that do not produce adverse events, enhancing acceptance and accessibility for patients; clinicians can better assess the true efficacy of the medication in treating the targeted symptoms. Overall, ensuring a dose free from adverse side effects is crucial for optimizing patient safety, treatment adherence, regulatory approval, therapeutic efficacy, and offering cost-effective long-term treatments.”

“These transformative discoveries mark a paradigm shift in Alzheimer’s treatment. This devastating disease significantly impairs cognitive function, memory, and daily functioning, leading to a decline in quality of life for affected individuals. As the disease progresses, individuals may experience difficulty with basic activities of daily living, leading to increased dependency and loss of autonomy. The global costs associated with dementia care, including medical expenses, long-term care, and lost productivity exceed $1 trillion annually. Our upcoming milestones with BMND08 are focused on pursuing a Breakthrough Therapy Designation and halting MCI progression towards Alzheimer's disease,” concluded Antalich.